GPT and Recurrent upper respiratory tract infections: Adverse events in the teriflunomide group at least 2% greater than in the placebo group were an increase in alanine aminotransferase (ALT), hair thinning, diarrhoea, paraesthesia, and upper respiratory tract infection [111].